Compugen Ltd. · NASDAQ:CGEN
Compugen — Investor Presentation (November 2020)
36 slides from Compugen's investor presentation, November 2020
Slide 1: Corporate Overview
CORPORATE OVERVIEW November 2020
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains “forward-looking statements” within the meaning of the the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements c
Slide 3: Our Vision: From Code to Cure
OUR VISION ® FROM CODE TO CURE Transforming patient lives by developing first- in-class therapeutics based on Compugen’s computational target discovery platform www.cgen.com I 3
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS Innovative Encouraging Preliminary Strategic Computational Immuno-Oncology Portfolio Clinical Data Collaborations Platform First-in-Class Drugs Well-Tolerated with Signals External Validation of From Code to Clinic of Anti-Tumor Activity Targets & Approach • Phase 1 drug candid
Slide 5: Strong Execution and Near-Term Value Drivers
STRONG EXECUTION AND NEAR-TERM VALUE DRIVERS COM701 COM902 • Presented encouraging data from monotherapy and combination • Initiated Phase 1 dose escalation study all comers with Opdivo® dose escalation studies at AACR in patients with advanced solid malignancies in • Completed enrollment in combina
Slide 6: Leadership Team
LEADERSHIP TEAM Management Team Board Of Directors Paul Sekhri Chairman of the Board Anat Cohen-Dayag, PhD Anat Cohen-Dayag, PhD Ari Krashin Henry Adewoye, MD President & CEO, Director President and CEO Chief Financial & Operating Officer SVP & Chief Medical Officer Jean-Pierre Bizzari, MD Director
Slide 7: Strategic Advisors
STRATEGIC ADVISORS Industry Veterans, Renowned Oncologists and Immunologists Scientific Advisory Board Drew Pardoll, MD, PhD Antoni Ribas, MD, PhD Nils Lonberg, PhD Elliott Sigal, MD, PhD Chairman Former SVP, Oncology Discovery Biology Strategic Advisor Multi-year strategic collaboration Bristol Mye
Slide 8: Computational Discovery Platform
COMPUTATIONAL DISCOVERY PLATFORM www.cgen.com I
Slide 9: From Target Discovery to Clinical Validation
FROM TARGET DISCOVERY TO CLINICAL VALIDATION Proven Computational Approach to Discover New Biological Pathways for I/O Drug Targets RNASeq Novel Targets PROPRIETARY COMPUTATIONAL TOOLS AND ALGORITHMS Single Cell RNA First-in-Class Drug Candidates Curation Annotation Integration Microarray Novel Biom
Slide 10: Significant Unmet Need
SIGNIFICANT UNMET NEED 70-80% of Patients Non-responsive to Approved Cancer Immunotherapies PD-1 monotherapy/combination activity across indications • New drug targets aimed to address 100 ~20-30% Average non-responsive patient populations Overall response Rate % 90 80 Response Rate 70 65 58 58 • Me
Slide 11: Versatile Computational Discovery Platforms to Address Immune Resistance
VERSATILE COMPUTATIONAL DISCOVERY PLATFORMS TO ADDRESS MULTIPLE MECHANISMS OF IMMUNE RESISTANCE INFLAMED EXCLUDED/SUPPRESSED DESERT/NON-INFLAMED IMMUNE CHECKPOINT MYELOID IMMUNE RESISTANCE PLATFORM PLATFORM PLATFORM Advanced pipeline with 3 Early-stage pipeline with Technology in development program
Slide 12: Compugen's Immuno-Oncology Pipeline
COMPUGEN’S IMMUNO-ONCOLOGY PIPELINE From Code to Cure® PROGRAM PARTNER DISEASE STAGE OF DEVELOPMENT Expansion to Lung, COM701 Breast, Ovarian PHASE 1 PVRIG inhibitor Endometrial, Colorectal COM701 + Opdivo® * PHASE 1 PVRIG + PD-1 inhibitors COM701 + Opdivo® + BMS-986207 Expansion to Ovarian, PHASE 1
Slide 13: Innovative Cancer Immunotherapy Portfolio
INNOVATIVE CANCER IMMUNOTHERAPY PORTFOLIO: TO OVERCOME RESISTANCE TO IMMUNOTHERAPY www.cgen.com I
Slide 14: PVRIG: A Novel Checkpoint Target in the TIGIT/DNAM Axis
PVRIG: A NOVEL CHECKPOINT TARGET IN THE TIGIT/DNAM AXIS TUMOR CELL / • PVRIG – internally discovered by APC Compugen’s discovery platform • DNAM axis – two parallel and PVRL2 PVR complementary inhibitory pathways (PVRIG & TIGIT) DNAM • PVRL2 broadly expressed in PVRIG PD-L1 positive and negative tum
Slide 15: PVRIG Pathway in the DNAM Axis
PVRIG PATHWAY IN THE DNAM AXIS Potential Intersection Between PVRIG/TIGIT and PD-1 Pathways Support Combination Approach to Overcome Immunotherapy Resistance Biomarker and Biology-Driven Drug Combination Approach www.cgen.com I 15 15
Slide 16: COM701: First-in-Class Anti-PVRIG Antibody
COM701: A FIRST-IN-CLASS ANTI-PVRIG THERAPEUTIC MONOCLONAL ANTIBODY Ongoing Phase 1 study in patients with advanced solid Combination therapy strategy based on deep tumors who have exhausted standard treatment options understanding of DNAM axis biology treatments • Signals of anti-tumor activity in
Slide 17: Biomarker-Driven Approach Supports COM701
BIOMARKER-DRIVEN APPROACH SUPPORTS COM701 MONOTHERAPY AND COMBINATION THERAPY TARGET INDICATIONS EXPRESS HIGHER PVRL2 RELATIVE TO PVR • PVRL2 highly expressed in many solid tumors • PVRL2 commonly expressed in both PD-L1 positive and negative tumors • PVRIG may serve as a dominant inhibitory checkpo
Slide 18: COM701: Synergistic T Cell Activation with PD-1 or TIGIT Inhibitors
COM701: SYNERGISTIC T CELL ACTIVATION WITH PD-1 OR TIGIT INHIBITORS COM701 +/- anti-TIGIT COM701 +/- anti-PD-1 Triple combination Whelan, et al., Cancer Immunol Res. 2019 www.cgen.com I 18 18
Slide 19: PVRIG Knockout or Inhibition Reduces Tumor Growth in Mouse Models
PVRIG KNOCKOUT OR INHIBITION REDUCES TUMOR GROWTH IN COMBINATION WITH PD-L1 OR TIGIT IN MOUSE MODELS PVRIG KO MICE (MC38) anti-PVRIG + anti-PD-L1 (CT26) PVRIG + TIGIT Double KO (B16) Control IgG Wild-type Mean Tumor Volume (mm3 ) 2500 WT a PD-L1 PVRIG -/- KO WT + αPD-L1 a PD-L1+ a-mPVRIG TIGIT -/- 2
Slide 20: PVRIG and TIGIT: Complementary but Distinct Pathways
PVRIG AND TIGIT – COMPLEMENTARY BUT DISTINCT PATHWAYS PVRIG preferentially TIGIT preferentially binds PVRL2 binds PVR Differentially expressed in Differentially expressed on Differentially expressed in tumor types immune cell types the tumor microenvironment PVRL2 expression is more TIGIT and PVRIG
Slide 21: PVRL2 and PVR Exhibit Distinct Expression Patterns
PVRL2 AND PVR ALSO EXHIBIT DISTINCT EXPRESSION PATTERNS PVRL2 expression is more dominant compared to PVR in certain cancers, such as breast, endometrial, and ovarian More dominant expression of PVRL2 on some tumor types T / NK Cells Dendritic Cells High PVRL2 expression Tumor Cells Myeloid Cells Hi
Slide 22: PVRIG/PVRL2 Pathway Expressed on Key Immune Cell Populations
PVRIG/PVRL2 PATHWAY EXPRESSED ON KEY IMMUNE CELL POPULATIONS INVOLVED IN T CELL PRIMING PVRIG expression on TSCM cells PVRL2 expression across various dendritic cell types PVRIG TIGIT PD-1 RNA Expression PVRL2 TSCM Exhausted TSCM Exhausted TSCM Exhausted NSCLC sample; single cell RNA analysis of Gau
Slide 23: COM701 Clinical Programs
COM701 CLINICAL PROGRAMS Phase 1 Arm A Phase 1/2 Monotherapy Monotherapy Triple Combination Dose Escalation Dose Escalation Cohort Expansion Escalating doses of COM701 with fixed doses of (20 patients; progressed on SOC) Opdivo® + BMS-986207 Study Objectives All-comers NSCLC, Ovarian, Breast, • Safe
Slide 24: COM701: Signals of Anti-Tumor Activity
COM701: SIGNALS OF ANTI-TUMOR ACTIVITY Monotherapy and Combination Dose Escalation Study (AACR Data Presentation, April 2020) • COM701 well-tolerated, no DLTs reported as monotherapy and in combination with Opdivo® Safety Profile • 16 patients in Arm A; 12 patients in Arm B • Two confirmed partial r
Slide 25: Summary of Investigator-Assessed Response
SUMMARY OF INVESTIGATOR-ASSESSED RESPONSE (per RECIST v1.1 DLT-EVALUABLE POPULATION) Data from Monotherapy and Combination Dose Escalation Study Arm A (N = 16) Arm B (N = 12) N (%) N (%) Overall Response rate (CR+PR) 1 (6) 1 (8) Disease control rate (CR+PR+SD) 11 (69) 9 (75) Durable stable disease (
Slide 26: COM701 Monotherapy Dose Escalation – Arm A
COM701 MONOTHERAPY DOSE ESCALATION – ARM A Data cut www.cgen.com I 26 26
Slide 27: COM701 Dose Escalation + Fixed Dose Opdivo – Arm B
COM701 DOSE ESCALATION + FIXED DOSE OPDIVO® – ARM B www.cgen.com I 27 27
Slide 28: COM701: Encouraging Preliminary Clinical Data
COM701: ENCOURAGING PRELIMINARY CLINICAL DATA Confirmed Partial Responses and Durable Stable Disease in Highly Refractory Patients Patients with durable Confirmed partial Maximum prior anti- 2 responses 6 responses of stable disease ≥ 6 months 15 cancer therapies Encouraging signals of anti-tumor ac
Slide 29: COM902: Anti-TIGIT Therapeutic Monoclonal Antibody
COM902: ANTI-TIGIT THERAPEUTIC MONOCLONAL ANTIBODY Potential to Fully Address DNAM Axis in Combination with COM701 Potential Best- High affinity – femtomolar – anti-TIGIT monoclonal antibody in-Class In vitro activity comparable or superior to TIGIT antibodies in clinical development Data-driven Pre
Slide 30: COM902: A High Affinity Anti-TIGIT Antibody
COM902: A HIGH AFFINITY ANTI-TIGIT ANTIBODY High affinity TIGIT binding Superior binding compared Enhances tumor infiltrating (650 fM) to clinical TIGIT benchmarks T-cells activation ex-vivo 4500 4000 3500 3000 gMFI 2500 2000 1500 1000 0.001 0.01 0.1 1 10 100 1000 [mAb] (Binding Site, nM) SITC, Nove
Slide 31: COM902 Phase 1 Study
COM902 PHASE 1 STUDY Identifier: NCT04354246 Monotherapy Dose Escalation Study Objectives All-comers, advanced malignancies who exhausted available treatment options • Safety & tolerability • PK/PD Administered IV every 3 weeks • Clinical activity Up to 7 dose escalation cohorts may be evaluated unt
Slide 32: Strategic Collaborations: External Validation of Internally Discovered Targets
STRATEGIC COLLABORATIONS: EXTERNAL VALIDATION OF INTERNALLY DISCOVERED TARGETS www.cgen.com I
Slide 33: Partnerships with Leading Pharma Companies
PARTNERSHIPS WITH LEADING PHARMA COMPANIES Clinical Trial Collaboration Development and License Agreement and Equity Investment Commercialization Agreement March 2018 October 2018, Amended February 2020 August 2013 $12M strategic equity investment Over $30M in upfront and milestone $10M upfront paym
Slide 34: Financial Position
FINANCIAL POSITION CASH • ~$133 million as of September 30, 2020 BALANCE • No Debt GROSS CASH EXPENDITURES • 2020 expected gross cash expenditures ~$27 million (excludes any cash inflows) • ~$1.2 billion (October 2020) MARKET • NASDAQ (CGEN); Nasdaq Biotechnology Index CAPITALIZATION • TASE (CGEN.TA
Slide 35: Strong Execution and Near-Term Value Drivers
STRONG EXECUTION AND NEAR-TERM VALUE DRIVERS COM701 COM902 • Presented encouraging data from monotherapy and combination • Initiated Phase 1 dose escalation study all comers with Opdivo® dose escalation studies at AACR in patients with advanced solid malignancies in • Completed enrollment in combina
Slide 36: Corporate Overview
CORPORATE OVERVIEW November 2020